Published in Gene Therapy Weekly, May 9th, 2002
Annual revenues for the year ended December 31, 2001, increased 59%, or $591,981 to $1,599,044 compared with revenues of $1,007,063 in fiscal 2000.
The company's fourth quarter revenues increased $214,113, or 88% to $457,768 in 2001 compared with revenues of $243,655 in the fourth quarter of 2000. The net loss for 2001 was $2.7 million, or $0.27 per share, compared with a net loss in 2000 of $5.04 million, or $0.54 per share.
The company is the developer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.